tiletamine hydrochloride has been researched along with Atherogenesis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiba, T; Ishigami, A; Kaneko, E; Kondo, Y; Maruyama, N; Shimokado, K; Shinozaki, S; Umezawa, K | 1 |
1 other study(ies) available for tiletamine hydrochloride and Atherogenesis
| Article | Year |
|---|---|
A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice.
Topics: Adiponectin; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Benzamides; Body Weight; Cholesterol; Cyclohexanones; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Triglycerides; Tumor Necrosis Factor-alpha | 2006 |